Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIFT: Management of GERD in NICU Infants
NCT06114836Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Mar 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of omeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Nationwide Children's Hospital. Primary endpoints: Improvement or maintenance of oral feeding and/or absence of GERD symptoms at 4 weeks, Acid Reflux Index at 4 weeks and 3 more. Started Mar 2024; status: recruiting.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06114836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114836.